Rice Hall James & Associates LLC Boosts Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Rice Hall James & Associates LLC boosted its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 25.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 621,665 shares of the company's stock after purchasing an additional 124,438 shares during the period. Rice Hall James & Associates LLC owned approximately 1.72% of scPharmaceuticals worth $2,835,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Perkins Capital Management Inc. acquired a new stake in shares of scPharmaceuticals during the first quarter worth $53,000. Balanced Rock Investment Advisors LLC lifted its position in scPharmaceuticals by 9.2% during the 1st quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company's stock worth $287,000 after acquiring an additional 4,827 shares during the period. Virtu Financial LLC purchased a new stake in scPharmaceuticals during the 1st quarter valued at about $90,000. Assenagon Asset Management S.A. increased its holdings in shares of scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company's stock valued at $316,000 after purchasing an additional 52,870 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company's stock worth $375,000 after purchasing an additional 11,269 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Stock Performance

Shares of NASDAQ:SCPH traded down $0.08 during midday trading on Friday, reaching $4.07. The company's stock had a trading volume of 146,602 shares, compared to its average volume of 245,137. The company has a quick ratio of 3.66, a current ratio of 4.84 and a debt-to-equity ratio of 4.32. The stock has a fifty day moving average of $4.68 and a 200 day moving average of $4.52. scPharmaceuticals Inc. has a twelve month low of $3.24 and a twelve month high of $6.71. The firm has a market capitalization of $203.62 million, a PE ratio of -2.61 and a beta of 0.15.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share for the quarter, hitting the consensus estimate of ($0.44). The company had revenue of $8.05 million for the quarter, compared to the consensus estimate of $8.04 million. scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. On average, equities analysts expect that scPharmaceuticals Inc. will post -1.34 EPS for the current fiscal year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.